Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled TLC19 in Healthy Volunteers
NCT04697654Phase 1Completed
- Sponsor
- Taiwan Liposome Company
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ISPM19 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Taiwan Liposome Company. Primary endpoint: Incidence of Adverse Events. Started Oct 2020; status: completed.
02
Drugs
ISPM19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04697654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697654.